MAY 08, 2019 12:49 PM PDT

Drug for Huntington Disease Successfully Lowers Culprit Protein

WRITTEN BY: Nouran Amin

In a study published in the New England Journal of Medicine, a drug for the first time was shown to successfully lower the abnormal protein that causes the debilitating Huntington disease (HD) in patients without any adverse reactions. The culprit protein is mutant huntingtin protein that becomes toxic in the central nervous system of Huntington disease patients.

https://hdsa.org/wp-content/uploads/2019/03/what_is_hd_overview_hd_disease_full.jpg

“HD affects the whole brain, but certain areas are more vulnerable than others. Pictured above are the basal ganglia – a group of nerves cell clusters, called nuclei. These nuclei play a key role in movement and behavior control and are the parts of the brain most prominently affected in early HD.”

Credit: hdsa.org

The study is clinical trial designed to see if the drug halts or slows down progression of Huntington disease. The drug, sponsored by Ionis Pharmaceuticals and Hoffmann-La Roche, was administered monthly to 34 early HD patients via an injection directly into the cerebrospinal fluid (CSF)—which is the location of the protein.

"This is a tremendously exciting and promising result for patients and families affected by this devastating genetic brain disorder," said Dr. Blair Leavitt, neurologist and director of research at the Centre for Huntington Disease at UBC. "For the first time, we have evidence that a treatment can not only decrease levels of the toxic disease-causing protein in patients, but that it is also safe and very well tolerated."

Learn more about Huntington Disease (HD):

Huntington disease (HD) develops adulthood and progresses to causes abnormal involuntary movements, psychiatric symptoms and dementia. It is a fatal a genetic neurological disease caused by a single known mutation. There is currently no effective treatments that have been proven to slow the progression of the disease.

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
FEB 24, 2021
Drug Discovery & Development
How Caffeine Changes the Brain?
FEB 24, 2021
How Caffeine Changes the Brain?
Caffeine is the worlds most consumed psychoactive substance which includes coffee, cola or an energy drink. However, res ...
APR 14, 2021
Cancer
Cell Viability- Where to Begin?
APR 14, 2021
Cell Viability- Where to Begin?
Written By: Author As I pondered the title of this article, my thoughts immediately went back to a request by my Ph.D. a ...
MAY 06, 2021
Drug Discovery & Development
Tweaked Version of Ketamine Could Solve the Opioid Crisis
MAY 06, 2021
Tweaked Version of Ketamine Could Solve the Opioid Crisis
Medications that manage post-operative pain are some of the main entry points to opioid addiction and overdose in the US ...
MAY 15, 2021
Neuroscience
Eye Scans May Indicate Early Signs of Alzheimer's
MAY 15, 2021
Eye Scans May Indicate Early Signs of Alzheimer's
Researchers from the University of California San Francisco have found that retinal scans can detect changes in blood ve ...
JUN 04, 2021
Drug Discovery & Development
Stem Cell Transplants May Treat Patients with Type 2 Diabetes
JUN 04, 2021
Stem Cell Transplants May Treat Patients with Type 2 Diabetes
Researchers at the Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam have found that stem cel ...
JUN 17, 2021
Drug Discovery & Development
FDA Approval of First New Alzheimer's Drug in Two Decades Sparks Controversy
JUN 17, 2021
FDA Approval of First New Alzheimer's Drug in Two Decades Sparks Controversy
The FDA recently approved a new drug known as Adulhelm, or aducanumab, to treat Alzheimer’s disease. The first new ...
Loading Comments...